查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球散瞳治療市場 - 2023-2030
市場調查報告書
商品編碼
1374828

全球散瞳治療市場 - 2023-2030

Global Mydriasis Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

瞳孔散大也稱為瞳孔散大。當眼睛的黑色中心比正常情況大時，就會發生瞳孔散大。這種情況可能是由眼科檢查中滴眼藥水、任何藥物或藥物的副作用或外傷引起的。由於光線和情緒事件的變化，瞳孔會自然擴張，但異常的瞳孔擴張可能是由醫療狀況引起的。瞳孔的正常大小在強光下為 2 至 4 毫米，在低光源下（散瞳）為 4 至 8 毫米。

而且，大多數時候，散瞳的瞳孔會自行恢復到正常大小。如果瞳孔突然放大、外傷後發生或引起頭痛和神智不清，需要立即就醫。散瞳的治療包括戴太陽眼鏡以降低對陽光的敏感度，特別是常使用光致變色鏡片和偏光鏡片，佩戴假體隱形眼鏡以改善因外傷、藥物濫用康復以及在某些情況下引起的瞳孔大小變化而導致的眼睛外觀手術被認為是修復眼睛受傷造成的損傷。

市場動態：促進因素

擴大採用眼科解決方案

眼科解決方案的日益普及預計將在預測期內推動市場發展。由於其非侵入性性質，眼藥水（例如眼藥水）通常最受瞳孔散大患者的青睞。這種偏好可以提高患者對處方治療的依從性，從而獲得更好的結果。由於採用率不斷提高，許多公司都專注於開發眼科解決方案。

例如，2023年9月27日，Viatris Inc.發布消息稱，美國食品藥物管理局（FDA）批准0.75% RYZUMVI（酚妥拉明滴眼液）用於治療腎上腺素激動劑（如去氧腎上腺素）或藥物引起的藥物引起的瞳孔散大。副交感神經阻斷劑（例如托吡卡胺）。

此外，許多臨床試驗正在進行中，以開發新型眼科解決方案，這些解決方案在散瞳治療方面顯示出更好的效果。關於定期眼科檢查和早期干涉眼部疾病重要性的公眾意識活動和教育舉措有助於採取更積極主動的眼保健方法。這反過來又推動了眼科解決方案主要用於治療瞳孔散大的應用。

此外，許多監管部門的批准，例如 FDA 對新型眼科解決方案的批准，增加了患者對使用眼科解決方案的信任。例如，2023 年2 月13 日，Ocuphire Pharma, Inc. 獲得了美國食品藥物管理局(FDA) 的Nyxol（酚妥拉明眼用溶液0.75%）新藥申請(NDA) 受理，用於治療藥物引起的瞳孔散大。

此外，散瞳盛行率的增加、新療法的監管批准增加、臨床試驗和研究活動的增加、對散瞳、散瞳鏡片及其治療的認知的提高以及開發新療法的技術進步預計將在預測期內推動市場。

限制

與手術相關的併發症、與眼藥水相關的副作用、隱形眼鏡的不適、治療瞳孔散大的高成本以及缺乏更好和快速的治療等因素預計將阻礙市場。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 按治療類型分類
  • 按銷售管道分類
  • 按地區分類

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 眼科解決方案的採用率不斷提高
    • 限制
      • 與手術相關的併發症
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 管道分析
  • 未滿足的需求
  • 專利分析
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第 7 章：按治療類型

  • 太陽眼鏡
    • 光致變色鏡片
    • 偏光鏡片
    • 其他
  • 假體隱形眼鏡
  • 手術
  • 藥物濫用康復
  • 眼藥水
    • 阿托品
    • 髓藥酯
    • 後馬托品
    • 去氧腎上腺素
    • 其他
  • 其他

第 8 章：按銷售管道

  • 配銷通路
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 最終用戶
    • 醫院
    • 眼科診所
    • 復健中心
    • 門診手術中心
    • 學術及研究機構
    • 其他

第 9 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 11 章：公司簡介

  • Omeros Corporation
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Thea Laboratories
  • Ocuphire Pharma, Inc.
  • Alcon Inc.
  • Hoya Vision
  • Maui Jim USA, Inc.
  • Safilo Group SpA
  • Global Calcium Pvt Ltd
  • VISION EASE
  • ZEISS Group

第 12 章：附錄

簡介目錄
Product Code: PH7347

Overview

Mydriasis is also known as dilated pupils. Mydriasis occurs when the black center of the eyes is larger than normal. The condition may be caused by dilating eye drops from an eye exam, the side effects from any drugs or medication or traumatic injury. Pupils naturally dilate due to changes in light and emotional events, but unusual pupil dilation could be the result of a medical condition. A pupil's normal size is 2 to 4 millimeters in bright light and 4 to 8 millimeters in dim light (dilated).

Moreover, most of the time, dilated pupils will back to normal size on their own. If pupils dilate suddenly, occur after a traumatic injury or cause headaches and confusion, need to seek medical attention immediately. The treatment of mydriasis includes wearing sunglasses to reduce sunlight sensitivity, especially photochromic lenses and polarized lenses are commonly used, wearing prosthetic contact lenses to improve the appearance of eyes as the result of varying pupil size caused by trauma, substance abuse rehabilitation and in some situations surgery is considered to repair eye damage from injury.

Market Dynamics: Drivers

Increasing adoption of ophthalmic solutions

The increasing adoption of ophthalmic solutions is expected to drive the market over the forecast period. Ophthalmic solutions, such as eye drops are often mostly preferred by mydriasis patients due to their non-invasive nature. This preference increases patient compliance with the prescribed treatments, leading to better outcomes. Due to the increasing adoption, many companies are focussing on developing ophthalmic solutions.

For instance, on September 27, 2023, Viatris Inc. released that the U.S. Food and Drug Administration (FDA) approved RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

Moreover, many clinical trials are going on for the development of novel ophthalmic solutions that show better results in mydriasis treatment. Public awareness campaigns and educational initiatives about the importance of regular eye examinations and early intervention for eye conditions are contributing to a more proactive approach to eye care. This, in turn, drives the adoption of ophthalmic solutions mostly in the treatment of mydriasis.

Further, many regulatory approvals such as FDA approvals for novel ophthalmic solutions increase the trust in patients for the usage of ophthalmic solutions. For instance, on February 13, 2023, Ocuphire Pharma, Inc. cleared the U.S. Food and Drug Administration (FDA) acceptance for the New Drug Application (NDA) for Nyxol (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis.

Further, the increasing prevalence of mydriasis, rising regulatory approvals for novel therapeutics, increasing clinical trials and research activities, increasing awareness about mydriasis, mydriatic lenses and their treatment and technological advancements in developing novel treatments are expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the surgery, side effects associated with the eye drops, the discomfort of the contact lenses, the high cost of the treatment of mydriasis and lack of better and quick treatment are expected to hamper the market.

Segment Analysis

The global mydriasis treatment market is segmented based on treatment type, sales channel and region.

The sunglasses segment accounted for approximately 42.2% of the mydriasis treatment market share

The sunglasses segment is expected to hold the largest market share over the forecast period. Sunglasses with photochromic lenses and polarized lenses are most commonly used to reduce sunlight sensitivity. Sometimes, individuals with mydriasis experience increased sensitivity to light, in such situations, sunglasses can help manage this sensitivity of the light by reducing the amount of light entering the eyes.

In addition, after certain eye surgeries or other mydriatic medical procedures, patients may be advised to wear sunglasses to protect the eyes from bright light and it reduces discomfort. While mydriatic sunglasses do not directly treat mydriasis, they can provide symptomatic relief by minimizing discomfort caused by bright light, glare, or intense sunlight.

Further, the wide availability and acceptability of the mydriatic sunglasses helps to hold the largest market share. In addition, their wide adoption also increases the demand for the sunglasses.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies for developing novel ophthalmic solutions and advanced eyewear such as sunglasses and contact lenses. The presence of major players actively performing in clinical trials, leads to the launch of novel therapeutics and alternative treatment options for the treatment of mydriasis.

Furthermore, the increasing research activities especially in the United States also helps to develop more advanced therapeutics for the better management of the symptoms in the early stages. As the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics and devices, which results in better patient outcomes.

Competitive Landscape

The major global players in the mydriasis treatment market include: Omeros Corporation, Thea Laboratories, Ocuphire Pharma, Inc., Alcon Inc., Hoya Vision, Maui Jim USA, Inc., Safilo Group S.p.A., Global Calcium Pvt Ltd, VISION EASE, ZEISS Group and among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global mydriasis treatment market. The pandemic created unprecedented challenges for pharmaceutical industries worldwide. During the pandemic, many clinical trials, research activities and regulatory approvals are temporarily disrupted or postponed due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these treatment medications and eyewear globally.

Market Segmentation

By Treatment Type

  • Sunglasses
    • Photochromic Lenses
    • Polarized Lenses
    • Others
  • Prosthetic Contact Lenses
  • Surgery
  • Substance Abuse Rehabilitation
  • Eye Drops
    • Atropine
    • Mydrilate
    • Homatropine
    • Phenylephrine
    • Others
  • Others

By Sales Channel

  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • End-User
    • Hospitals
    • Ophthalmic Clinics
    • Rehabilitation Centers
    • Ambulatory Surgical Centers
    • Academic and Research Institutes
    • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global mydriasis treatment market segmentation based on treatment type, sales channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of mydriasis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global mydriasis treatment market report would provide approximately 53 tables, 49 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Sales Channel
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Ophthalmic Solutions
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with the Surgery
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. Patent Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Sunglasses*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Photochromic Lenses
    • 7.2.4. Polarized Lenses
    • 7.2.5. Others
  • 7.3. Prosthetic Contact Lenses
  • 7.4. Surgery
  • 7.5. Substance Abuse Rehabilitation
  • 7.6. Eye Drops
    • 7.6.1. Atropine
    • 7.6.2. Mydrilate
    • 7.6.3. Homatropine
    • 7.6.4. Phenylephrine
    • 7.6.5. Others
  • 7.7. Others

8. By Sales Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 8.1.2. Market Attractiveness Index, By Sales Channel
  • 8.2. Distribution Channel*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Hospital Pharmacies
    • 8.2.4. Retail Pharmacies
    • 8.2.5. Online Pharmacies
  • 8.3. End-User
    • 8.3.1. Hospitals
    • 8.3.2. Ophthalmic Clinics
    • 8.3.3. Rehabilitation Centers
    • 8.3.4. Ambulatory Surgical Centers
    • 8.3.5. Academic and Research Institutes
    • 8.3.6. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. UK
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Omeros Corporation*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Thea Laboratories
  • 11.3. Ocuphire Pharma, Inc.
  • 11.4. Alcon Inc.
  • 11.5. Hoya Vision
  • 11.6. Maui Jim USA, Inc.
  • 11.7. Safilo Group S.p.A.
  • 11.8. Global Calcium Pvt Ltd
  • 11.9. VISION EASE
  • 11.10. ZEISS Group

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us